Vanguard Fiduciary Trust’s GlucoTrack GCTK Stock Holding History

Vanguard Fiduciary Trust’s Portfolio GCTK Stock Details GCTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,722	Closed	-$3.07K	–	4109
2026 Q1	$3.07K	Buy	+4,722	New	+$10K	﹤0.01%	4044

Other funds holding GCTK

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

GIPW

Granite Islands Private Wealth Guilford, Connecticut $135M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Fiduciary Trust's GCTK Position: Q2 2026 in Review

Vanguard Fiduciary Trust sold out of GlucoTrack (GCTK) in Q2 2026, closing a stake of 4,722 shares — an estimated $3.07K sold.

Vanguard Fiduciary Trust first reported a position in GCTK in Q1 2026 and held it in 1 quarter. The position peaked at $3.07K in Q1 2026. 18 funds tracked by Wall St. Rank hold GCTK as of Q2 2026.

Vanguard Fiduciary Trust reported no remaining GlucoTrack position as of Q2 2026 after selling out during the quarter.
Vanguard Fiduciary Trust sold 4,722 GlucoTrack shares in Q2 2026, an estimated $3.07K.
Vanguard Fiduciary Trust first reported a position in GlucoTrack in Q1 2026 and held it in 1 quarter.
Vanguard Fiduciary Trust's GlucoTrack position peaked at $3.07K in Q1 2026.
18 funds tracked by Wall St. Rank held GlucoTrack as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.